
Crizanlizumab
CAS No. 1690318-25-2
Crizanlizumab( —— )
Catalog No. M36878 CAS No. 1690318-25-2
Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 821 | Get Quote |
![]() ![]() |
5MG | 1311 | Get Quote |
![]() ![]() |
10MG | 2119 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCrizanlizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionCrizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease.
-
DescriptionCrizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1690318-25-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020).
molnova catalog



related products
-
2-Fluoroadenosine
2-Fluoroadenosine is a potent inhibitor of lymphocyte-mediated cytolysis.
-
FPR Agonist 43
FPR Agonist 43 is a dual agonist of formyl peptide receptor 1 and formyl peptide receptor 2 (FPR2)/ALX.
-
5-Methoxypiperonal
Reference standards.